--- title: "U.S. stock night market fluctuations: Cabaletta Bio rose 7.57% in the night market, boosted by a combination of $150 million financing and positive clinical data, driving the stock price surge" type: "News" locale: "en" url: "https://longbridge.com/en/news/285167723.md" description: "Cabaletta Bio rose 7.57% in the after-hours market; BeiGene fell 1.69% in the after-hours market, with a transaction volume of USD 254,200; Abivax SA rose 2.45% in the after-hours market, with a transaction volume of USD 222,100; Intellia Therapeutics rose 0.36% in the after-hours market, with a transaction volume of USD 140,100" datetime: "2026-05-05T07:36:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285167723.md) - [en](https://longbridge.com/en/news/285167723.md) - [zh-HK](https://longbridge.com/zh-HK/news/285167723.md) --- # U.S. stock night market fluctuations: Cabaletta Bio rose 7.57% in the night market, boosted by a combination of $150 million financing and positive clinical data, driving the stock price surge **U.S. Stock Night Market Movements** Cabaletta Bio rose 7.57% in the night market. Based on recent key news: 1. On May 4, Cabaletta Bio announced a $150 million underwritten offering, with a price of $2.90 per share. This news drove the stock price up, and the company expects to receive approximately $150 million in total proceeds. 2. On May 4, the company released clinical data for rese-cel in the RESET-PV trial, showing significant biological and clinical activity, further enhancing market confidence. 3. On May 4, analysts maintained a buy rating on Cabaletta Bio, setting target prices of $13 and $30, anticipating that future data releases will further enhance the company's valuation. The biotechnology sector has performed strongly recently, with noticeable capital inflows. **Stocks with High Trading Volume in the Industry** BeiGene fell 1.69% in the night market. Based on recent key news: 1. On May 4, Wells Fargo announced a target price of $400 per share for BeOne Medicines. This news may have affected investor confidence in the biopharmaceutical industry, leading to a decline in BeiGene's stock price. 2. On May 4, financial reports released by Refinitiv indicated that BeiGene's quarterly performance as of March 31, 2025, exceeded expectations; however, the quarterly performance as of December 31, 2024, fell short of expectations, which may negatively impact investor sentiment. 3. On May 4, the market held a cautious outlook on the overall prospects of the biopharmaceutical industry, with increasing investor concerns about future profitability leading to stock price volatility. The biopharmaceutical industry faces uncertainties, and investors are cautious. Abivax SA rose 2.45% in the night market. Based on recent key news: 1. On May 5, Abivax SA announced the repurchase of warrants and a $45 million American Depositary Shares offering. This move strengthened the company's cash flow, expected to last until the fourth quarter of 2027, driving the stock price up. 2. On May 5, Abivax SA released an announcement detailing the specifics of the repurchase and offering, further stabilizing investor confidence and promoting stock price increases. 3. On May 5, Abivax SA published relevant information through EQS News, ensuring market transparency and increasing investor trust, resulting in a stock price increase. Market confidence in the biotechnology sector has strengthened, with noticeable capital inflows. Intellia Therapeutics rose 0.36% in the night market. Based on recent key news: 1. On May 1, Intellia Therapeutics granted inducement awards to 43 new employees. This move aims to attract talent and enhance the company's commitment to innovation and growth. This news may have boosted market confidence in the company's future development, driving the stock price up. Source: GlobeNewswire 2. On May 1, Intellia granted restricted stock units covering 208,850 shares under the 2024 inducement plan. This move demonstrates the company's long-term incentive and development plans for employees, which may enhance investor confidence. Source: GlobeNewswire 3. There are no other significant news recently. The biopharmaceutical industry is driven by innovation, with a noticeable influx of capital ### Related Stocks - [CABA.US](https://longbridge.com/en/quote/CABA.US.md) - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) - [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md) - [NTLA.US](https://longbridge.com/en/quote/NTLA.US.md) ## Related News & Research - [Cabaletta Bio Q1 net loss widens as R&D costs rise](https://longbridge.com/en/news/286406375.md) - [Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors | IMUX Stock News](https://longbridge.com/en/news/286894992.md) - [ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/286893590.md) - [TGT Stock Alert: What to Know as Target Taps Former Walmart Exec](https://longbridge.com/en/news/286957668.md) - [Hormel Foods Corporation Declares Quarterly Dividend | HRL Stock News](https://longbridge.com/en/news/286830009.md)